Publicación:
Eficacia de la Denervación simpática renal como ultimo escalafón terapéutico en hipertensión refractaria, revisión de la literatura.

dc.contributor.authorDULCEY SARMIENTO, LUIS ANDRESspa
dc.contributor.authorCastillo Blanco, Jhon Fredyspa
dc.contributor.authorTheran Leon, Juan Sebastianspa
dc.contributor.authorCaltagirone Miceli, Raimondospa
dc.date.accessioned2025-07-21T07:12:32Z
dc.date.accessioned2025-08-05T14:25:29Z
dc.date.available2025-07-21T07:12:32Z
dc.date.available2025-08-05T14:25:29Z
dc.date.issued2025-07-21
dc.description.abstractAntecedentes: La hipertensión arterial acarrea una elevadísima carga de morbimortalidad por sus efectos deletéreos, pese al arsenal terapéutico tan amplio en algunos pacientes es refractaria. Estimaciones anteriores han colocado la carga global de enfermedad en adultos entre 30 y 32%, con la región de Asia Oriental y el Pacífico teniendo la mayor carga absoluta con poco más de 439 millones afectados. Además de las repercusiones en la salud, la hipertensión también conlleva costos económicos significativos. Metodología: Revisión amplia de la literatura sobre las actualizaciones en el área correspondiente al manejo de la hipertensión arterial refractaria y la utilidad de la terapia de denervación renal. Conclusiones: A pesar del tratamiento farmacológico bien establecido, la hipertensión sigue contribuyendo en gran medida a las muertes por enfermedades no transmisibles. Dada la bien conocida asociación de la hipertensión con enfermedades cardiovasculares adversas, la importancia del control de la presión arterial nunca ha sido más crucial. Tradicionalmente, el manejo farmacológico ha sido el pilar de la atención, sin embargo, con una carga de enfermedad cada vez mayor, ahora se están considerando enfoques alternativos e innovadores. Los sistemas de ablación basados en catéter mínimamente invasivos, dirigidos a los nervios simpáticos renales, se han propuesto como una forma más permanente de controlar la presión arterial.spa
dc.description.abstractBackground: Hypertension carries an extremely high burden of morbidity and mortality due to its deleterious effects, despite such a broad therapeutic arsenal in some patients it is refractory. Previous estimates have placed the global burden of disease in adults at between 30 and 32%, with the East Asia and Pacific region having the highest absolute burden with just over 439 million affected. In addition to the health repercussions, hypertension also carries significant economic costs.  Methodology: Extensive review of the literature on updates in the area corresponding to the management of refractory arterial hypertension and the usefulness of renal denervation therapy. Conclusions: Despite well-established pharmacological treatment, hypertension continues to be a major contributor to deaths from noncommunicable diseases. Given the well-known association of hypertension with adverse cardiovascular disease, the importance of blood pressure control has never been more crucial. Traditionally, pharmacological management has been the mainstay of care, however, with an increasing burden of disease, alternative and innovative approaches are now being considered. Minimally invasive catheter-based ablation systems, targeting the renal sympathetic nerves, have been proposed as a more permanent way to control blood pressure.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.26752/cuarzo.v30.n1.640
dc.identifier.eissn2500-7181
dc.identifier.issn0121-2133
dc.identifier.urihttps://repositorio.juanncorpas.edu.co/handle/001/440
dc.identifier.urlhttps://doi.org/10.26752/cuarzo.v30.n1.640
dc.language.isospaspa
dc.publisherFundación Universitaria Juan N. Corpasspa
dc.relation.bitstreamhttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/640/555
dc.relation.citationendpage31
dc.relation.citationissue1spa
dc.relation.citationstartpage26
dc.relation.citationvolume30spa
dc.relation.ispartofjournalRevista Cuarzospa
dc.relation.referencesForouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013. Lancet. 2015;386(10010): 2287–323.spa
dc.relation.referencesMills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 Countries. Circulation. 2016;134(6):441–50.spa
dc.relation.referencesHird T, Zomer E, Owen A, Magliano D, Liew D, Ademi Z. Productivity burden of hypertension in Australia. Hypertension. 2019;73(4):777–84.spa
dc.relation.referencesEttehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.spa
dc.relation.referencesSPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.spa
dc.relation.referencesChobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.spa
dc.relation.referencesDaugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42.spa
dc.relation.referencesYang Q, Chang A, Ritchey MD, Loustalot F. Antihypertensive medication adherence and risk of cardiovascular disease among older adults: a population-based cohort study. J Am Heart Assoc. 2017;6(6):e006056.spa
dc.relation.referencesKatholi RE, Rocha-Singh KJ. The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance? Prog Cardiovasc Dis. 2009;52(3):243–8.spa
dc.relation.referencesEsler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11(1):3–20.spa
dc.relation.referencesSchultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension. 2007;50(1):6–13.spa
dc.relation.referencesStella A, Zanchetti A. Functional role of renal afferents. Physiol Rev. 1991;71(3):659–82.spa
dc.relation.referencesSchiller AM, Haack KK, Pellegrino PR, Curry PL, Zucker IH. Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure. Am J Physiol Regul Integr Comp Physiol. 2013;305(8):R886–92.spa
dc.relation.referencesSmithwick RH, Thompson JE. Splanchnicectomy for essential hypertension: results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4.spa
dc.relation.referencesKrum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.spa
dc.relation.referencesSymplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7.spa
dc.relation.referencesKrum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.spa
dc.relation.referencesSymplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.spa
dc.relation.referencesEsler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9.spa
dc.relation.referencesKandzari DE, Bhatt DL, Sobotka PA, O'Neil WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35(9):528– 35.spa
dc.relation.referencesKandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.spa
dc.relation.referencesKandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, et al. The SPYRAL HTN global clinical trial program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFFMED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J. 2016;171(1):82–91.spa
dc.relation.referencesOsborn JW, Banek CT. Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation. Hypertension. 2018;71(3):383–8.spa
dc.relation.referencesBöhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–51.spa
dc.relation.referencesMahfoud F, Böhm M, Azizi M, Pathak, Zaleski ID, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27.spa
dc.rightsLUIS ANDRES DULCEY SARMIENTO, Jhon Fredy Castillo Blanco, Juan Sebastian Theran Leon, Raimondo Caltagirone Miceli - 2025spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0spa
dc.sourcehttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/640spa
dc.subjectHypertensioneng
dc.subjectTreatmenteng
dc.subjectTherapyeng
dc.subjectDrugseng
dc.subjectHipertensiónspa
dc.subjectTratamiento,spa
dc.subjectTerapiaspa
dc.subjectFármacosspa
dc.titleEficacia de la Denervación simpática renal como ultimo escalafón terapéutico en hipertensión refractaria, revisión de la literatura.spa
dc.title.translatedEfficacy of renal sympathetic denervation as the last therapeutic echelon in refractory hypertension, literature revieweng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublicationspa

Archivos